Lewy Body Dementia and Current Research Studies
Today in the United States, there are no medications approved for the treatment of dementia with Lewy bodies (DLB) and only a single drug approved for Parkinson's disease dementia (PDD; the other major form of Lewy body dementia [LBD]), and that is only approved to treat hallucinations and delusions. That is changing. In fact, within the last 6 months alone, researchers have reported promising results from three different Phase 2 clinical trials in people with LBD. In this presentation, you will learn the results of these trials, hear about scientific breakthroughs that are speeding progress in LBD trials, and learn where to find out more if you or someone you know may be interested in volunteering for ongoing or future research studies.
Zoom link provided upon registration.
Presenter
Keith Fargo, PhD
Director of Scientific Initiatives
Lewy Body Dementia Association
Keith N. Fargo, PhD, is the Director of Scientific Initiatives at the Lewy Body Dementia Association. Dr. Fargo earned his PhD in Neuroscience from Indiana University, where his research focused on the effects of hormones on the structure and function of spinal cord neurons that control movement. In his current role at the Lewy Body Dementia Association, he is responsible for the research activities of the LBDA, including the flagship LBDA Research Centers of Excellence, a network of 20 of the nation’s leading academic medical institutions focused on advancing our understanding of the disease, improving care, and carrying out clinical trials for Lewy body dementias.
